REGN REGENERON PHARMACEUTICALS, INC. Insider Trading

Regeneron Director Zoghbi sold 1,638 shares for $1,279,811.86 in 11 separate transactions on 2026-02-19, reducing holdings by -49.0%.

Director Huda Y Zoghbi executed 11 separate sales on 2026-02-19, totaling 1,638 shares (1.6K shares) for $1,279,811.86 at prices ranging from $774.68 to $790.00 with a blended average of $781.33, reducing her post-transaction holdings to 1,703 shares against a pre-transaction position of 3,341 shares. The current share price of $787.04 sits near the top of the 52-week range ($483.07–$812.27) at only -3.1% from the 52-week high, and the stock has appreciated +4.4% over the past 30 days. Regeneron's fundamentals remain solid with net income of $1,460,000,000.00 ($1.5B) on revenue of $3,754,300,000.00 ($3.8B), though annual revenue growth is modest at +1.0%, and the P/E of 15.83 suggests reasonable valuation. Zoghbi's cross-ticker track record shows just 1 prior sell with a 90-day return of +7.7% and a well-timed rate of 0.00%, and her sole prior trade at REGN on 2024-01-02 also posted a 90-day return of +7.7%, indicating the stock has historically risen after her sales rather than fallen.

SVP Controller Pitofsky sold 2,036 shares of REGN for $1.6M in 11 transactions on 2026-02-09

Jason Pitofsky, SVP Controller at Regeneron Pharmaceuticals, executed 11 separate sales totaling 2,036 shares for $1,585,058.14 on 2026-02-09, reducing his holdings from 6,308 shares to 4,272 shares (-32.3%). The blended average price across these transactions was $778.52, within the stock's recent trading range and just 4.1% below the 52-week high of $812.27. His prior sell transaction at REGN (2024-08-07) posted a 90-day return of -22.5%, representing 1 of 1 prior sells as well-timed at the 90-day mark. The company fundamentals show solid profitability (net income $1.5B on revenue $3.8B) with modest annual revenue growth of +1.0% and a P/E of 15.67, providing no obvious red flag context for the sale. Without knowledge of whether this sale is scheduled under a 10b5-1 plan or discretionary, the stock's recent 90-day uptrend (+12.1%) and prior sale timing pattern merit investor monitoring.

Director Bonnie L Bassler sold 1,500 shares of REGN at $800.00 (1.2M total); held 3,203 pre-sale, 1,703 post-sale (-46.8%).

Director Bonnie L Bassler sold 1,500 shares at $800.00 on 2026-01-07, reducing her holdings from 3,203 to 1,703 shares, a 46.8% reduction in position. The sale occurred near the upper end of the 52-week range ($483.07–$812.27) and within 1.4% of the 52-week high, while the stock has appreciated 41.9% over 90 days and 15.7% over 30 days. The company maintains solid fundamentals with $3.8B quarterly revenue, $1.5B net income, and a reasonable 16.44 P/E valuation, though annual revenue growth of 8.3% reflects a moderating growth trajectory. This substantial reduction in a director's stake merits disclosure scrutiny, though the absence of a scheduled trading plan flag and the concentrated nature of the transaction (single sale) warrant examination of context and intent.

Director Christine A. Poon sells 6,500 shares ($4.3M) at $654.27 avg; holds 5,064 shares post-transaction.

Director Christine A. Poon executed 6 separate sales totaling 6,500 shares for $4,252,745.32 on 2025-10-29, reducing her holding by 56.2% from 11,564 shares to 5,064 shares. The blended average sale price of $654.27 is modestly above the current price of $651.80, though notably below the 52-week high of $928.61. Her prior 5 sales at REGN (all on 2024-08-15) showed strong timing discipline at the 90-day horizon, with all 5 trades posting negative 90-day returns—a 100.00% well-timed rate. Her cross-ticker track record similarly reflects a 100.00% 90d well-timed rate across 12 prior sells. The material reduction in her position, combined with a track record of disciplined prior exits at this ticker, suggests deliberate portfolio reduction rather than routine liquidation.

McCourt Marion (EVP Commercial) sold 1,000 shares of REGN for $1,054,060.00 on 2024-10-01.

McCourt Marion sold 1,000 shares at $1,054.06, reducing holdings by 7.2%, after the stock had declined 13.2% over the prior 30 days and is now 15.6% below its 52-week high of $1,201.76. His cross-ticker track record shows a 50.00% well-timed rate on prior sells, indicating moderate historical precision in exit timing. However, his same-ticker REGN history shows mixed results: only 1 of 2 prior sells were well-timed at the 90-day mark, with his most recent REGN sale on 2024-09-03 down 13.9% at the 30-day check. The transaction occurs in a fundamentally stable company with $3.5B quarterly revenue, 7.8% annual growth, and a P/E of 22.06, providing no signal of distress. The sale appears discretionary and modest relative to his remaining 12.9K share position.

McCourt Marion (EVP Commercial) sold 1,000 shares of REGN at $1,178.73 on 2024-09-03; currently -4.3% from 52-week high.

McCourt Marion sold 1,000 shares at $1,178.73, reducing holdings by 7.2% from 13,931 to 12,931 shares. The sale occurred near the 52-week peak ($1,201.76), with the stock now trading -4.3% below that high. His prior three REGN sales (June, July, August 2024) all saw gains in the following 30 days (+4.5%, +3.1%, +11.7%), and the June sale posted a +20.9% 90-day return, indicating prior REGN sales were not well-timed on a 90-day horizon. Over his cross-ticker history, his 3 prior sells averaged a 90-day return of +20.9% with a 0.00% well-timed rate, meaning they consistently missed subsequent gains. This September sale follows the same monthly pattern and timing window as the prior three REGN transactions, occurring as the stock has rallied +7.9% in 30 days and +14.7% in 90 days.

CFO Fenimore sells 5,680 shares (99.6% of holdings) for $6.8M, reducing stake to 25 shares

Christopher R. Fenimore, SVP Finance & CFO, executed 10 separate sales on 2024-08-28 totaling 5,680 shares for $6,846,262.22, reducing his holdings from 5,705 shares to just 25 shares—a near-complete exit of his position. The blended average sale price of $1,205.33 occurred within the 52-week range ($775.18–$1,201.76) and 1.9% below the 52-week high. At his prior REGN sales on 2024-02-09, 0 of 5 prior sells were well-timed at the 90-day mark, with all five resulting in modest positive 90-day returns (ranging 1.4%–1.8%), meaning the stock rose after his prior exits. The scale and breadth of this liquidation—virtually eliminating executive ownership—deserves scrutiny, particularly given Regeneron's solid near-term fundamentals (FY revenue growth +7.8%, P/E 25.63) and the stock's strong recent momentum (+9.4% in 30 days, +20.3% in 90 days). Investors should monitor whether this represents a strategic shift in the CFO's equity commitment or reflects other considerations.

Director Christine A Poon sold 10,838 shares of REGN for $12.6M across 7 transactions on 2024-08-15, reducing holdings by 83.3%.

Christine A Poon (Director) executed 7 separate sales totaling 10,838 shares for $12,552,284.50 at prices ranging from $1,155.72 to $1,161.32 on 2024-08-15, leaving 2,172 shares post-transaction. This represents a -83.3% reduction of her pre-transaction holdings of 13,010 shares. The scale of the reduction—nearly a complete exit from her publicly-disclosed position—exceeds routine portfolio activity. Notably, her prior 5 sales at REGN were uniformly well-timed at the 90-day mark, with all prior REGN trades showing negative 90-day returns (-1.6% to -5.0%), indicating a historical pattern of selling before price declines. The current stock price of $1196.88 stands 0.0% from the 52-week high and has appreciated +12.5% over 30 days and +20.4% over 90 days since the August 15 sale, showing post-sale upward momentum. This transaction warrants close observation to determine whether the sustained recent price strength represents a departure from her prior pattern of well-timed exits.

EVP Andrew J Murphy sold 6,363 shares of REGN for $7,337,504.87 across 18 transactions on 2024-08-14

Murphy executed 18 separate sales totaling 6,363 shares for $7,337,504.87, reducing his holdings from 54,669 to 48,306 shares (-11.6% reduction). The transactions occurred at prices ranging from $1,140.31 to $1,158.78, with a blended average of $1,153.15, near the current price of $1,175.33 and within 0.0% of the 52-week high. His prior five sales at REGN (all on 2024-03-14) each showed negative 30-day returns (-6.0% to -5.2%) followed by positive 90-day returns (+6.7% to +7.6%), establishing a pattern of sales that have not been well-timed at the 90-day mark; all 5 prior trades failed to capture the subsequent upside. This current sale occurs at historically elevated valuations (P/E 25.55) on a stock up 7.3% in 30 days and 19.6% in 90 days, but without a defined trigger (no FLAG indicating a 10b5-1 plan) the motivation remains undisclosed.

EVP Stahl sold 5,197 shares at $1,084.54 blended avg for $5.6M; retains 50.1K shares post-sale.

Neil Stahl, EVP Research and Development at Regeneron, executed 6 separate sales totaling 5,197 shares for $5,636,346.27 on 2024-08-08, reducing his holdings from 55.3K to 50.1K shares (-9.4%). The stock has since appreciated to $1121.09, trading near its 52-week high of $1131.24, and has gained 13.9% over the trailing 90 days. Notably, Stahl's prior 5 open-market sales at REGN (all on 2024-02-07) posted subsequent 30-day and 90-day gains ranging from +1.7% to +2.4%, with a 0% well-timed rate at the 90-day mark—meaning the stock rose materially after each prior sale. His cross-ticker track record shows only a 30% well-timed sell rate across 10 prior dispositions. The current sale occurred near the stock's 52-week high, though the insider retains a substantial 50.1K-share position, reflecting continued meaningful ownership in the $105.3B market-cap enterprise.